Needham reportedly cut its Veracyte price target by $23 per share after the Company’s November 4, 2026 outlook reset on its Decipher Prostate test. An investigation into potential securities law violations is underway on behalf of VCYT shareholders who lost money.

NEW YORK, Nov. 12, 2026 /PRNewswire/ — Needham reportedly cut its price target on Veracyte (NASDAQ: VCYT) by $23 per share, from $69 to $46, after the Company’s November 4, 2026 third-quarter report. VCYT shares declined as the market weighed a weaker outlook for the Decipher Prostate test. If you are holding VCYT at a loss, or already sold at one, this investigation concerns you. Shareholders who lost money are encouraged to submit their loss information now , or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com  or (212) 363-7500.

Shares fell on the same day Veracyte reported third-quarter revenue of $151.8 million and authorized a $100 million share buyback. The Company narrowed full-year 2026 revenue guidance to $590 million to $593 million, down from $590 million to $596 million. The new top end is below the cited analyst estimate of $593.894 million.

Needham’s reported $46 target is roughly 33% below its prior $69 target. Attention after the report centered on lower 2027 growth expectations and competitive pressure on Decipher Prostate. Levi & Korsinsky is investigating potential securities law violations on behalf of VCYT investors who suffered losses.

VCYT investors with losses following the November 4 report can request a no-cost review of their losses  or call (212) 363-7500.

Levi & Korsinsky, LLP  — Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Billions recovered.

Frequently Asked Questions About the VCYT Investigation

Q: What is the deadline to contact Levi & Korsinsky about VCYT?  A: No deadline has been announced in the VCYT investigation at this time. Contacting the firm now ensures your losses are considered if the investigation proceeds to legal action.

Q: Which statements are being investigated as potentially misleading?  A: The investigation concerns whether Veracyte’s statements about the growth outlook for its Decipher Prostate test were accurate and complete. The stock price declined after the Company disclosed on November 4, 2026 that Decipher Prostate volume was below its expectations.

Q: What is a lead plaintiff and why does it matter?  A: If the investigation proceeds to legal action, a lead plaintiff is the investor the court appoints to represent the group of affected investors. Lead plaintiffs are typically investors with the largest documented losses. Contacting the firm during the investigation phase preserves that option.

Q: What documents do I need to participate?  A: You will need brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my VCYT shares — can I still recover losses?  A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought VCYT and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?  A: There is no upfront cost to submit your information and review whether you may be eligible to recover. If you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

Q: Do I need to go to court or give testimony?  A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/veracyte-vcyt-securities-investigation-notice—levi–korsinsky-302937429.html

SOURCE Levi & Korsinsky, LLP